<div id="readability-page-1"><p><span>LifeMD (NASDAQ:LFMD - Get Free Report)</span> was downgraded by Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note issued to investors on Saturday.</p><ul><li>Can the New CEO Revive This Struggling Telehealth Stock?</li></ul><p>Several other equities research analysts also recently commented on the company. Cantor Fitzgerald  restated an &#34;overweight&#34; rating on shares of LifeMD in a report on Tuesday, March 10th. BTIG Research  reiterated a &#34;buy&#34; rating and set a $10.00 price target on shares of LifeMD in a report on Monday, May 4th. HC Wainwright upped their price target on LifeMD from $9.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, March 11th. Mizuho upgraded LifeMD from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and upped their price target for the stock from $6.00 to $8.00 in a report on Monday, March 16th. Finally, Weiss Ratings upgraded LifeMD from a &#34;sell (e+)&#34; rating to a &#34;sell (d)&#34; rating in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $9.14.</p><p><b>View Our Latest Stock Report on LifeMD</b></p><h2>LifeMD Stock Up 6.5%</h2><ul><li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans </li></ul><p>NASDAQ LFMD opened at $4.78 on Friday. The company has a market cap of $227.53 million, a price-to-earnings ratio of 95.62 and a beta of 2.03. LifeMD has a 52 week low of $2.56 and a 52 week high of $15.84. The business has a 50 day moving average price of $3.87 and a 200-day moving average price of $3.93. </p><p>LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The firm had revenue of $50.16 million for the quarter, compared to the consensus estimate of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%.  On average, equities research analysts anticipate that  LifeMD will post 0.01 earnings per share for the current year. </p><h2>Institutional Investors Weigh In On LifeMD</h2><ul><li>LifeMD Can Surge on Its GLP-1 Offerings  </li></ul><p>Several institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in  LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company's stock worth $270,000 after buying an additional 2,235 shares in the last quarter.  Tower Research Capital LLC TRC grew its holdings in  LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock worth $64,000 after buying an additional 2,452 shares in the last quarter.  SG Americas Securities LLC boosted its position in  LifeMD by 13.8% in the fourth quarter. SG Americas Securities LLC now owns 25,298 shares of the company's stock worth $86,000 after purchasing an additional 3,061 shares during the last quarter.  Invesco Ltd. boosted its position in  LifeMD by 18.8% in the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company's stock worth $83,000 after purchasing an additional 3,870 shares during the last quarter.  Finally, Rhumbline Advisers boosted its position in  LifeMD by 8.7% in the second quarter. Rhumbline Advisers now owns 53,589 shares of the company's stock worth $730,000 after purchasing an additional 4,281 shares during the last quarter. Institutional investors own  35.52% of the company's stock. </p><h2>LifeMD Company Profile</h2> (Get Free Report)<p>LifeMD <span>NASDAQ: LFMD<span></span></span> is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services. </p><p>LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than LifeMD</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in LifeMD Right Now?</h2><p>Before you consider LifeMD, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.</p><p>While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LFMD

<p>Wall Street Zen downgraded LifeMD (NASDAQ:LFMD) from a "hold" to a "sell" rating. Despite this, several analysts maintain positive outlooks, with Cantor Fitzgerald and BTIG Research issuing "overweight" and "buy" ratings, respectively. LifeMD's stock opened at $4.78, with a market cap of $227.53 million. The company reported a quarterly EPS of ($0.20), missing estimates, but had revenue of $50.16 million. Institutional investors hold 35.52% of the stock, which has a 52-week range of $2.56 to $15.84. Analysts rate it as a "Moderate Buy" with an average target price of $9.14.</p>

LifeMD (NASDAQ:LFMD) Cut to Sell at Wall Street Zen